This is a working overview of Epitalon, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-02 and is reviewed periodically as new material appears.
Residue composition is the property that most cleanly separates verified material from mislabelled samples. Alanine, glutamate, aspartate and glycine appear in that order from the N-terminus, and the two acidic residues sit in the middle of the chain. Because the peptide is short, it can be produced by solid-phase synthesis and characterised by mass spectrometry without ambiguity. Any reported sample whose measured mass departs substantially from 390 daltons is a different compound or a degraded mixture rather than epitalon.
Epitalon is a synthetic tetrapeptide whose four residues are alanine, glutamate, aspartate and glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9 and its monoisotopic mass is near 390.35 daltons. The peptide carries two acidic side chains, so it is neutral to negatively charged in most aqueous buffers. Published reference summaries usually list it under both spellings, epitalon and epithalon, and treat the two names as the same material.
The proposed relationship between epitalon and pineal function is a central part of its background. Khavinson's group reported that short peptides corresponding to regions of larger pineal proteins could influence gene expression in cells. Epitalon was framed as a synthetic analogue of an active fragment rather than a direct isolation product. Whether the tetrapeptide reproduces the effects of the parent extract is an open question, because comparative studies are limited and the parent extract itself is not a single defined substance.
Interest in epitalon is usually discussed within the broader field of short peptide bioregulators, a category that includes other synthetic di-, tri-, and tetrapeptides studied by the same research group. These compounds share a common rationale: that small fragments of tissue-derived proteins can retain biological activity and can be produced reproducibly. The category as a whole remains outside mainstream pharmacological consensus, and epitalon specifically has a limited presence in independent, non-Russian research literature, which shapes how its evidence base is described.
Epitalon is a synthetic tetrapeptide with the amino acid sequence alanine-glutamate-aspartate-glycine, abbreviated Ala-Glu-Asp-Gly or AEDG. It was developed by the Russian researcher Vladimir Khavinson and colleagues during work on peptide bioregulators derived from the pineal gland. The compound is short enough to be produced by standard solid-phase peptide synthesis and is typically handled as a lyophilized white powder. Its small size distinguishes it from larger pineal peptides such as epithalamin, a complex extract from which the tetrapeptide was conceptually derived.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H22N4O9 | Derived from the four constituent residues |
| Molecular mass | About 390.35 Da | Monoisotopic value, confirmed by mass spectrometry |
| Residue sequence | Ala-Glu-Asp-Gly | Read from the N-terminus to the C-terminus |
| Common synonyms | Epithalon; AEDG | Both forms appear in reference catalogues |
| Net charge near neutral pH | Negative | Two acidic side chains give a low isoelectric point |
Literature searches for this compound must account for several spelling variants. Indexing databases contain epitalon, epithalon, epithalone, and AEDG, and relevant records are scattered across Russian-language and English-language journals that do not consistently cross-cite. Early publications describe the parent extract as a mixture of many peptides, whereas later work addresses the single synthetic tetrapeptide. That shift in nomenclature complicates comparison between studies, because extract data and tetrapeptide data are sometimes cited interchangeably. A search strategy omitting the alternate spellings will return an incomplete set of references.
Reported biological findings come mainly from cell culture and rodent experiments. Those studies describe changes in telomerase catalytic subunit expression, melatonin rhythm amplitude, and antioxidant enzyme activity after peptide exposure. Human data are sparse and consist of small trials with limited blinding and inconsistent endpoints. The proposed mechanisms remain hypotheses rather than established facts, and there is no consensus on whether effects observed in animals carry over to people. Independent replication outside the original research groups is limited, which is a recognised gap in the published literature.
The parent extract epithalamin was characterised as a low-molecular-weight fraction of pineal tissue rather than a single defined chemical entity. Researchers fractionated it and tested successive fragments for activity, a screening approach typical of peptide discovery work in that era. Epitalon emerged from that process as one of the shorter sequences of interest. Because the original extract was never fully resolved into individual components, claims about which constituent drives a given effect rest on inference. This distinction matters when reading older reports that attribute extract observations to the tetrapeptide itself.
Epitalon is a synthetic tetrapeptide whose sequence is alanine-glutamate-aspartate-glycine, written in single-letter code as AEDG. The four residues are joined by three peptide bonds, giving a linear backbone with no branching and no disulfide bridges. Its calculated molecular mass for the free form is approximately 390.3 daltons, a figure that rises when the compound is supplied as an acetate or trifluoroacetate salt. Because the chain is short, the molecule is defined entirely by its residue order rather than by any folded three-dimensional structure.
The compound is described in the literature as a derivative of epithalamin, a preparation obtained from bovine pineal tissue. Work on this peptide family was carried out mainly by a research group in Saint Petersburg beginning in the 1980s, and the substance was later registered for clinical use in Russia under the name Epitalon. Outside that region it is generally treated as a research chemical rather than an approved medicine. Statements about its biological activity rest on a relatively small number of studies, and independent replication remains limited.
Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and its calculated monoisotopic mass is approximately 390.35 daltons. The compound does not occur naturally as a free peptide; it is produced by solid-phase peptide synthesis. Because it contains two acidic residues and no basic residues, the neutral form carries a net negative charge at physiological pH. This charge profile influences how the peptide behaves in solution and during chromatographic analysis.
Laboratory-grade epitalon is typically supplied as a lyophilized powder. Purity is commonly assessed with reverse-phase high-performance liquid chromatography, often paired with mass spectrometry to confirm molecular identity. Amino acid analysis and peptide mapping can provide additional confirmation of sequence. Certificates of analysis for research materials frequently report purity above 95 percent, although the methods behind such figures vary between suppliers. The absence of a pharmacopeial monograph means that no single standardized assay defines the compound, so reported results depend on the analytical protocol chosen.
Storage recommendations center on limiting moisture, heat, and light. The dry powder is generally kept at minus 20 degrees Celsius, and some suppliers recommend minus 80 degrees for long-term archival. Once dissolved, solutions are usually aliquoted and frozen to avoid repeated freeze-thaw cycles, which can promote aggregation or degradation. Aqueous stability depends on pH and concentration, and buffered saline is often preferred over plain water for biological work. Stability data specific to epitalon remain limited, so general peptide-handling practices are applied by analogy rather than from product-specific validation.
Trump stated that if he were elected, he would increase deportations, send the U.S. military to the border, expand U.S. Immigration and Customs Enforcement detentions through workplace raids, deputize local law enforcement to handle border security, increase U.S. Customs and Border Protection funding, as well as finish building the wall on the southern border. Trump has said he will deport both legal and illegal immigrants. The New York Times reported that Trump was considering "an extreme expansion of his first-term crackdown on immigration", such as "preparing to round up undocumented people already in the United States on a vast scale and detain them in sprawling camps while they wait to be expelled". Trump stated his intention to deport 11 million people through the construction of detention camps and deploy the military, relying on presidential wartime powers under the 18th-century Alien Enemies Act. Trump made false claims of a "migrant crime wave" that are not supported by data, and provided no evidence to back up his claims. In regards to his anti-immigrant nativism, Trump's tone grew harsher from his previous time as president, and used fearmongering, racial stereotypes, and more dehumanizing rhetoric when referring to illegal immigrants.
The possibility of a militarized Japan has also been a continuous concern to the Chinese leadership since the late 1990s. In addition, China's military leadership has been reacting to and learning from the successes and failures of the United States Armed Forces during the Kosovo War, the 2001 invasion of Afghanistan, the 2003 invasion of Iraq, and the Iraqi insurgency. All these lessons inspired China to transform the PLA from a military based on quantity to one based on quality. Chairman Jiang Zemin officially made a "revolution in military affairs" (RMA) part of the official national military strategy in 1993 to modernize the Chinese armed forces. A goal of the RMA is to transform the PLA into a force capable of winning what it calls "local wars under high-tech conditions" rather than a massive, numbers-dominated ground-type war. Chinese military planners call for short decisive campaigns, limited in both their geographic scope and their political goals. In contrast to the past, more attention is given to reconnaissance, mobility, and deep reach. This new vision has shifted resources towards the navy and air force. The PLA is also actively preparing for space warfare and cyber-warfare. In 2002, the PLA began holding military exercises with militaries from other countries. From 2018 to 2023, more than half of these exercises have focused on military training other than war, generally antipiracy, or antiterrorism exercises involving combatting non-state actors.
=== Induced fit hypothesis === Daniel Koshland's theory of enzyme-substrate binding is that the active site and the binding portion of the substrate are not exactly complementary. The induced fit model is a development of the lock-and-key model and assumes that an active site is flexible and changes shape until the substrate is completely bound. This model is similar to a person wearing a glove: the glove changes shape to fit the hand. The enzyme initially has a conformation that attracts its substrate. Enzyme surface is flexible and only the correct catalyst can induce interaction leading to catalysis. Conformational changes may then occur as the substrate is bound. After the reaction products will move away from the enzyme and the active site returns to its initial shape. This hypothesis is supported by the observation that the entire protein domain could move several nanometers during catalysis. This movement of protein surface can create microenvironments that favour the catalysis.
=== RNAs involved in protein synthesis === Messenger RNA (mRNA) carries information about a protein sequence to the ribosomes, the protein synthesis factories in the cell. It is coded so that every three nucleotides (a codon) corresponds to one amino acid. In eukaryotic cells, once precursor mRNA (pre-mRNA) has been transcribed from DNA, it is processed to mature mRNA. This removes its introns—non-coding sections of the pre-mRNA. The mRNA is then exported from the nucleus to the cytoplasm, where it is bound to ribosomes and translated into its corresponding protein form with the help of tRNA. In prokaryotic cells, which do not have nucleus and cytoplasm compartments, mRNA can bind to ribosomes while it is being transcribed from DNA. After a certain amount of time, the message degrades into its component nucleotides with the assistance of ribonucleases. Transfer RNA (tRNA) is a small RNA chain of about 80 nucleotides that transfers a specific amino acid to a growing polypeptide chain at the ribosomal site of protein synthesis during translation. It has sites for amino acid attachment and an anticodon region for codon recognition that binds to a specific sequence on the messenger RNA chain through hydrogen bonding.
==== Apple juice ==== Apple juice, especially commercially produced products, interferes with the action of OATPs. This interference can decrease the absorption of a variety of commonly used medications, including beta blockers like atenolol, antibiotics like ciprofloxacin, and antihistamines like fexofenadine.
Sources: en.wikipedia.org
However, these salts also interact directly with proteins (which are charged and have strong dipole moments) and may even bind specifically (e.g., phosphate and sulfate binding to ribonuclease A). As a result, these interactions can lead to protein denaturation, the formation of artificial adducts, or the partial dissociation of (metal) cofactors, thus, disrupting the delicate balance between apo- and holometalloproteins. Ions that have a strong salting in effect such as I− and SCN− are strong denaturants, because they salt in the peptide group, and thus, interact much more strongly with the unfolded form of a protein than with its native form. Consequently, they shift the chemical equilibrium of the unfolding reaction towards unfolded protein.
== Partnerships == Dexcom entered into a partnership in 2015 with Google Life Sciences (which subsequently became Verily) to develop the Dexcom G7 Dexcom entered a non-exclusive agreement with Tandem Diabetes Care, Inc. in 2015 to allow the integration of its new G5 and G6 continuous glucose monitoring systems into Tandem's insulin pumps. Tandem Diabetes Care received FDA approval in December 2019 for Control-IQ, a closed-loop technology that uses Tandem's t:slim X2 insulin pump and the Dexcom G6 "to automatically increase, decrease, or stop the delivery of insulin in response to the glucose levels of people with Type 1 diabetes." In June 2019, Dexcom announced a collaboration with Companion Medical to enable the exchange of CGM data from Dexcom with insulin data from InPen into both companies' software applications. Dexcom entered into a partnership with Livongo, a digital chronic care management company, in January 2020 to share CGM data from the Dexcom G6 with Livongo's platform. This integration allowed Livongo to incorporate the CGM data along with other patient data. In February 2020, Dexcom and Insulet Corporation signed a non-exclusive, global agreement to combine current and future Dexcom continuous glucose monitoring systems with Insulet's tubeless insulin delivery Pod into the Omnipod Horizon System for automated insulin delivery. This allowed the ability to adjust insulin doses based on Insulet's algorithm or through their smartphone.
== Causes == Lymphocytosis is a feature of infection, particularly in children. In the elderly, lymphoproliferative disorders, including chronic lymphocytic leukemia and lymphomas, often present with lymphadenopathy and a lymphocytosis. Causes of absolute lymphocytosis include:
== History == SJS is named for Albert Mason Stevens and Frank Chambliss Johnson, American pediatricians who jointly published a description of the disorder in the American Journal of Diseases of Children in 1922.
Sources: en.wikipedia.org
It is a four-amino-acid peptide built from alanine, glutamate, aspartate and glycine in that order. Its formula is C14H22N4O9, and it is made by chemical synthesis rather than extracted from tissue. The synthetic peptide is a single defined molecule, unlike the pineal extracts it is often compared with.
No. The two spellings refer to the same tetrapeptide, and the difference reflects transliteration from Russian. Laboratories and catalogues use both forms interchangeably. The material is also indexed as AEDG, taken from the one-letter codes of its residues.
Epithalamin is a mixed preparation derived from animal pineal tissue and contains many peptides. Epitalon is one synthetic sequence chosen for study from that broader mixture. Statements about one do not transfer directly to the other.
Epitalon is a synthetic tetrapeptide composed of four amino acids: alanine, glutamate, aspartate, and glycine. It is written as Ala-Glu-Asp-Gly. The free peptide has a molecular weight of about 390 daltons and is normally supplied as a lyophilized powder.